EPISODE · Sep 10, 2021 · 12 MIN
Timothy Ko on Treating Addiction with DMT and Psychedelics | The CSE Podcast Ep3-S2
from The Exchange for Entrepreneurs™ Podcast · host CSE - Canadian Securities Exchange
CSE's Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they've been public and upcoming plans for clinical trials. Here's an overview of what Barrington and Timothy cover in this edition of the "Exchange for Entrepreneurs" podcast:0:00 - Catching up with Timothy Ko and Entheon Biomedical2:30 - What has happened since they listed on the CSE - Canadian Securities Exchange4:12 - Personalization through genetics6:20 - The genetics test kit8:30 - Pathway for clinical trials9:55 - What's coming next for investorsAbout Entheon Biomedical Corp.Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada. 🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-SubscribeSTAY CONNECTED WITH THE CSE =============================🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/🐦 - TWITTER: https://twitter.com/CSE_News📝 - BLOG: https://blog.thecse.com/🖥 - WEBSITE: https://thecse.com/🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe#AlwaysInvestedSTAY CONNECTED WITH THE CSE =============================📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/🐦 - X: https://x.com/CSE_News📝 - BLOG: https://blog.thecse.com/🖥 - WEBSITE: https://thecse.com/📖 - MAGAZINE: https://issuu.com/thecse/docs©2026 CNSX Markets Inc. All rights reserved.
Embed this episode
What this episode covers
CSE's Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they've been public and upcoming plans for clinical trials. Here's an overview of what Barrington and Timothy cover in this edition of the "Exchange for Entrepreneurs" podcast: 0:00 - Catching up with Timothy Ko and ...
NOW PLAYING
Timothy Ko on Treating Addiction with DMT and Psychedelics | The CSE Podcast Ep3-S2
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.